Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Annexon Inc

ANNX
Current price
5.07 USD -0.25 USD (-4.70%)
Last closed 5.36 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 534 448 992 USD
Yield for 12 month +48.68 %
1Y
3Y
5Y
10Y
15Y
ANNX
21.11.2021 - 28.11.2021

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California. Address: 1400 Sierra Point Parkway, Brisbane, CA, United States, 94005

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

16.4 USD

P/E ratio

Dividend Yield

Current Year

Last Year

Current Quarter

Last Quarter

+4 866 000 USD

Current Year

-3 267 000 USD

Last Year

-3 311 000 USD

Current Quarter

-846 000 USD

Last Quarter

+4 032 000 USD

Key Figures ANNX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -128 903 000 USD
Operating Margin TTM
PE Ratio
Return On Assets TTM -28.6 %
PEG Ratio
Return On Equity TTM -50.6 %
Wall Street Target Price 16.4 USD
Revenue TTM
Book Value 2.9 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM
Earnings per share -1.46 USD
Diluted Eps TTM -1.46 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics ANNX

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ANNX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation ANNX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM
Enterprise Value EBITDA -2.1896
Price Book MRQ 2.1486

Financials ANNX

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators ANNX

For 52 weeks

1.57 USD 8.4 USD
50 Day MA 5.08 USD
Shares Short Prior Month 7 569 377
200 Day MA 4.07 USD
Short Ratio 4.1
Shares Short 7 278 564
Short Percent 10.09 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

446.34 USD Microsoft Corporation -3.37 (-0.75%)
Detailed analytics

ETF funds


S

SLICHA

203.95 CHF UBS SLI A-dis -0.06 (-0.02%)
Detailed analytics

Metals


Gold

2339.94 USD Gold +11.09 (+0.48%)
Detailed analytics